The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

AC1LAD18     4-[3-(4-fluorophenyl)propyl]- 1,3-dimethyl...

Synonyms:
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Tetrahydropyridine

 

High impact information on Tetrahydropyridine

 

Chemical compound and disease context of Tetrahydropyridine

 

Biological context of Tetrahydropyridine

 

Associations of Tetrahydropyridine with other chemical compounds

 

Gene context of Tetrahydropyridine

  • 1. The tetrahydropyridine trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetrahydropyridine (t-THP), like MPTP, can undergo monoamine oxidase (MAO)-mediated conversion to a dihydropyridinium intermediate and subsequent metabolism to a pyridinium species. t-THP is also a better substrate for MAO B than MAO A [18].
  • The results of these studies provide additional insights into the steric features of the active site of MAO-B and predict that the area in which the C(4) substituent of the tetrahydropyridine ring resides lacks a reactive nucleophilic group [19].
  • CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo [20].
  • Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency [21].

References

  1. The effect of intraocular 6-hydroxydopamine on retinal processing of primates. Ghilardi, M.F., Marx, M.S., Bodis-Wollner, I., Camras, C.B., Glover, A.A. Ann. Neurol. (1989) [Pubmed]
  2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A. Basma, A.N., Heikkila, R.E., Nicklas, W.J., Giovanni, A., Geller, H.M. J. Neurochem. (1990) [Pubmed]
  3. Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Usuki, E., Van der Schyf, C.J., Castagnoli, N. Drug Metab. Rev. (1998) [Pubmed]
  4. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. Maroney, A.C., Finn, J.P., Connors, T.J., Durkin, J.T., Angeles, T., Gessner, G., Xu, Z., Meyer, S.L., Savage, M.J., Greene, L.A., Scott, R.W., Vaught, J.L. J. Biol. Chem. (2001) [Pubmed]
  5. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Horvath, T.L., Diano, S., Leranth, C., Garcia-Segura, L.M., Cowley, M.A., Shanabrough, M., Elsworth, J.D., Sotonyi, P., Roth, R.H., Dietrich, E.H., Matthews, R.T., Barnstable, C.J., Redmond, D.E. Endocrinology (2003) [Pubmed]
  6. Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators. Palmer, S.L., Mabic, S., Castagnoli, N. J. Med. Chem. (1997) [Pubmed]
  7. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. Pradines, A., Magazin, M., Schiltz, P., Le Fur, G., Caput, D., Ferrara, P. J. Neurochem. (1995) [Pubmed]
  8. Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol. Frølund, B., Kristiansen, U., Brehm, L., Hansen, A.B., Krogsgaard-Larsen, P., Falch, E. J. Med. Chem. (1995) [Pubmed]
  9. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Usuki, E., Pearce, R., Parkinson, A., Castagnol, N. Chem. Res. Toxicol. (1996) [Pubmed]
  10. Regioselective 6-endo cyclizations of 2-indolylacyl radicals: total synthesis of the pyrido[4,3-b]carbazole alkaloid guatambuine. Bennasar, M.L., Roca, T., Ferrando, F. J. Org. Chem. (2006) [Pubmed]
  11. Studies on the mechanism of MPTP oxidation by human liver monoamine oxidase B. Gessner, W., Brossi, A., Bembenek, M.E., Fritz, R.R., Abell, C.W. FEBS Lett. (1986) [Pubmed]
  12. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative. Barsoum, N.J., Gough, A.W., Sturgess, J.M., de la Iglesia, F.A. Neurotoxicology (1986) [Pubmed]
  13. Selective azetidine and tetrahydropyridine formation via Pd-catalyzed cyclizations of allene-substituted amines and amino acids. Rutjes, F.P., Tjen, K.C., Wolf, L.B., Karstens, W.F., Schoemaker, H.E., Hiemstra, H. Org. Lett. (1999) [Pubmed]
  14. Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Bryan-Lluka, L.J., Siebert, G.A., Pond, S.M. Naunyn Schmiedebergs Arch. Pharmacol. (1999) [Pubmed]
  15. Potential antidepressant properties of SR 57746A, a novel compound with selectivity and high affinity for 5-HT1A receptors. Cervo, L., Bendotti, C., Tarizzo, G., Cagnotto, A., Skorupska, M., Mennini, T., Samanin, R. Eur. J. Pharmacol. (1994) [Pubmed]
  16. 1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): an alicyclic MPTP-like neurotoxin. Youngster, S.K., Saari, W.S., Heikkila, R.E. Neurosci. Lett. (1987) [Pubmed]
  17. The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sullivan, J.P., Tipton, K.F. J. Neural Transm. Suppl. (1990) [Pubmed]
  18. Pharmacological properties of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetrahydropyridine and its pyridinium metabolite in mouse brain synaptosomes: a potential visual marker for substrates of MPTP-induced neurotoxicity. Klein, B.G., Kirby, M.L., Freeborn, E.R., Bloomquist, J.R. Prog. Neuropsychopharmacol. Biol. Psychiatry (2001) [Pubmed]
  19. Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors. Kalgutkar, A.S., Castagnoli, N. J. Med. Chem. (1992) [Pubmed]
  20. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito, M.S., Brown, E.M., Miller, M.S., Carswell, S. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  21. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency. Gwaltney, S.L., O'Connor, S.J., Nelson, L.T., Sullivan, G.M., Imade, H., Wang, W., Hasvold, L., Li, Q., Cohen, J., Gu, W.Z., Tahir, S.K., Bauch, J., Marsh, K., Ng, S.C., Frost, D.J., Zhang, H., Muchmore, S., Jakob, C.G., Stoll, V., Hutchins, C., Rosenberg, S.H., Sham, H.L. Bioorg. Med. Chem. Lett. (2003) [Pubmed]
 
WikiGenes - Universities